摘要
目的探讨血管紧张素Ⅱ受体拮抗剂伊贝沙坦对原发性高血压伴早期2型糖尿病肾病患者的降压效果和肾脏保护作用。方法轻、重度原发性高血压伴早期2型糖尿病肾病患者入选本实验,并随机分为伊贝沙坦组和氨氯地平组。于4周末根据血压调整剂量和疗程,6月后对患者进行评价。结果伊贝沙坦和氨氯地平组的降压及副作用相似。伊贝沙坦组和氨氯地平组在治疗后24 h尿白蛋白排泄率(24 h UAER)水平和24 h UAER的降低幅度方面比较差异有显著性(P<0.05)。其余指标差异无显著性。结论伊贝沙坦治疗轻、中度原发性高血压的有效率和氨氯地平近似且耐受性好,并可以减慢早期糖尿病肾病的蛋白进展而具有肾脏保护作用。
Objective To observe the effects of angiotensin Ⅱ receptor antagonist （ARB） Irbesartan in decreasing blood pressure and protecting kidney to the patients suffering from primary hypertension combined with earlier type Ⅱdiabetic nephropathy. Methods The patients with mild to moderate primary hypertension and earlier type Ⅱdiabetic nephropathy were divided into 2 groups randomly, Group A treated with Irbesartan and group B with Amlodipine. The period of treatment and doses were adjusted depending on the blood pressure on the fourth weekend. The curative effect of the two groups was evaluated 6 months later. Results There was significant difference in the post treatment 24h urinary albumin excretion rate （UAER） and the variation of UAER between the two groups （ P 〈 0.05 ）. There were not significant difference in the effect of decreasing blcod pressure, side effects and other aspects. Conclusions Irbesartan and Amlodipine have similar effects for mild to moderate primary hypertension. Irbesartan could defer effectively the development of proteinuria in diabetic nephropathy and protect the function of kidney.
出处
《实用全科医学》
2006年第5期598-599,共2页
Applied Journal Of General Practice
